3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le lundi 3 février 2020
Doi : 10.1016/j.jaad.2019.09.073
accepted : 9 September 2019
A crosslinked polymer skin barrier film for moderate to severe atopic dermatitis: A pilot study in adults

Melaney Bouthillette, BS a, b, , Daniela Beccati, PhD a, b, Ariya Akthakul, PhD a, b, Nithin Ramadurai, MS a, b, Amir Nashat, PhD b, Robert Langer, PhD c, d, e, f, R. Rox Anderson, MD c, g, h, Fernanda H. Sakamoto, MD, PhD g, h,
a Shiseido Americas Corporation, Cambridge, Massachusetts 
b Olivo Laboratories, LLC, Watertown, Massachusetts 
c Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 
d Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 
e David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 
f Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 
g Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts 
h Department of Dermatology, Harvard Medical School, Boston, Massachusetts 

Correspondence to: Fernanda H. Sakamoto, MD, PhD, Wellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 55 Fruit St, Thier 210, Boston, MA 02114.Wellman Center for PhotomedicineMassachusetts General HospitalDepartment of DermatologyHarvard Medical School55 Fruit St, Thier 210BostonMA02114Reprint requests: Melaney Bouthillette, BS, Shiseido Americas Corporation, One Kendall Square, 14-403, Cambridge, MA 02139.Shiseido Americas Corporation14-403CambridgeMA02139

Occlusive treatments are a mainstay in atopic dermatitis (AD) management but may not be well tolerated or lack compliance. A comfortable, semiocclusive, artificial skin barrier that is well tolerated, provides protection, and reduces water loss is needed.


To evaluate the potential tolerability and therapeutic benefits of a crosslinked polymer layer (XPL) in adults with AD.


A single-center, open-label pilot study was conducted involving 10 subjects with moderate to severe AD. Subjects applied XPL up to twice daily for 30 days on a selected treatment area. Investigator's Global Assessment, clinical signs of eczema, and pruritus were assessed on days 1, 3, 5, 15, and 30. Film durability and patient satisfaction were also evaluated.


Investigator's Global Assessment scores improved from moderate to severe at baseline to clear to almost clear in 8 of 9 patients at day 30. Pruritus improved from trace to severe itching (baseline) to all subjects having trace to no itching at day 30. There was 1 adverse event of mild exudative dermatitis.


The study was limited by small sample size, open-label design, and lack of control.


XPL may be an effective adjuvant in AD treatment. A larger study with a control group is warranted.

The full text of this article is available in PDF format.

Key words : atopic dermatitis, eczema, inflammatory skin diseases, itch, skin barrier function, silicone dressing

Abbreviations used : AD, BSA, IGA, XPL

 Funding sources: Supported by Olivo Laboratories, LLC.
 Disclosure: Ms Bouthillette, Drs Beccati and Akthakul, Mr Ramadurai, and Drs Nashat, Langer, Rox Anderson, and Sakamoto hold financial interest in Olivo Laboratories, LLC.
 IRB approval status: Reviewed and approved by Hummingbird IRB (2016-18).

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline